Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate

Lotte Wang, Chia-Ping H. Yang, Susan Band Horwitz, Pamela A. Trail, Anna M. Casazza

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

MA is an orally active PG derivative with an excellent safety profile that is used primarily for the treatment of carcinomas of the breast and endometrium. We investigated the potential application of MA as an MDR-reversal agent using cell culture and human tumor xenograft models. The reversing activity of MA in vitro was compared with that of PG and VER in two human MDR cell lines, the colon carcinoma HCT-116/VM46 and the breast carcinoma MCF-7/ADR, and in a murine cell line, J774.2. At concentrations as low as 3 μM, MA was capable of partially restoring sensitivity to Act D in the HCT-116/VM46 cells and sensitivity to DOX in the MCF-7/ADR cells. Although less effective than VER, MA was about 2.5 times more potent than PG in reversing MDR at equimolar concentrations. Increased accumulation of DOX in drugresistant cells that were treated simultaneously with MA was observed by flow cytometry. In vivo, using established human colon and breast carcinoma xenografts implanted s.c. in athymic mice, the combined therapy with MA and DOX resulted in enhanced antitumor activity relative to that of DOX alone in the MDR sublines. These results suggest that MA may be a promising clinical MDR-reversing agent.

Original languageEnglish (US)
Pages (from-to)96-102
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume34
Issue number2
DOIs
StatePublished - Mar 1994

Fingerprint

Megestrol Acetate
Multiple Drug Resistance
Heterografts
Cells
Phenotype
Flow cytometry
Colon
Cell culture
Breast Neoplasms
HCT116 Cells
Tumors
Cell Line
MCF-7 Cells
Endometrial Neoplasms
Derivatives
Nude Mice
Flow Cytometry
Cell Culture Techniques
Carcinoma
Safety

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate. / Wang, Lotte; Yang, Chia-Ping H.; Band Horwitz, Susan; Trail, Pamela A.; Casazza, Anna M.

In: Cancer Chemotherapy and Pharmacology, Vol. 34, No. 2, 03.1994, p. 96-102.

Research output: Contribution to journalArticle

@article{856f08fc674d4611b734a0941167d9d1,
title = "Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate",
abstract = "MA is an orally active PG derivative with an excellent safety profile that is used primarily for the treatment of carcinomas of the breast and endometrium. We investigated the potential application of MA as an MDR-reversal agent using cell culture and human tumor xenograft models. The reversing activity of MA in vitro was compared with that of PG and VER in two human MDR cell lines, the colon carcinoma HCT-116/VM46 and the breast carcinoma MCF-7/ADR, and in a murine cell line, J774.2. At concentrations as low as 3 μM, MA was capable of partially restoring sensitivity to Act D in the HCT-116/VM46 cells and sensitivity to DOX in the MCF-7/ADR cells. Although less effective than VER, MA was about 2.5 times more potent than PG in reversing MDR at equimolar concentrations. Increased accumulation of DOX in drugresistant cells that were treated simultaneously with MA was observed by flow cytometry. In vivo, using established human colon and breast carcinoma xenografts implanted s.c. in athymic mice, the combined therapy with MA and DOX resulted in enhanced antitumor activity relative to that of DOX alone in the MDR sublines. These results suggest that MA may be a promising clinical MDR-reversing agent.",
author = "Lotte Wang and Yang, {Chia-Ping H.} and {Band Horwitz}, Susan and Trail, {Pamela A.} and Casazza, {Anna M.}",
year = "1994",
month = "3",
doi = "10.1007/BF00685925",
language = "English (US)",
volume = "34",
pages = "96--102",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate

AU - Wang, Lotte

AU - Yang, Chia-Ping H.

AU - Band Horwitz, Susan

AU - Trail, Pamela A.

AU - Casazza, Anna M.

PY - 1994/3

Y1 - 1994/3

N2 - MA is an orally active PG derivative with an excellent safety profile that is used primarily for the treatment of carcinomas of the breast and endometrium. We investigated the potential application of MA as an MDR-reversal agent using cell culture and human tumor xenograft models. The reversing activity of MA in vitro was compared with that of PG and VER in two human MDR cell lines, the colon carcinoma HCT-116/VM46 and the breast carcinoma MCF-7/ADR, and in a murine cell line, J774.2. At concentrations as low as 3 μM, MA was capable of partially restoring sensitivity to Act D in the HCT-116/VM46 cells and sensitivity to DOX in the MCF-7/ADR cells. Although less effective than VER, MA was about 2.5 times more potent than PG in reversing MDR at equimolar concentrations. Increased accumulation of DOX in drugresistant cells that were treated simultaneously with MA was observed by flow cytometry. In vivo, using established human colon and breast carcinoma xenografts implanted s.c. in athymic mice, the combined therapy with MA and DOX resulted in enhanced antitumor activity relative to that of DOX alone in the MDR sublines. These results suggest that MA may be a promising clinical MDR-reversing agent.

AB - MA is an orally active PG derivative with an excellent safety profile that is used primarily for the treatment of carcinomas of the breast and endometrium. We investigated the potential application of MA as an MDR-reversal agent using cell culture and human tumor xenograft models. The reversing activity of MA in vitro was compared with that of PG and VER in two human MDR cell lines, the colon carcinoma HCT-116/VM46 and the breast carcinoma MCF-7/ADR, and in a murine cell line, J774.2. At concentrations as low as 3 μM, MA was capable of partially restoring sensitivity to Act D in the HCT-116/VM46 cells and sensitivity to DOX in the MCF-7/ADR cells. Although less effective than VER, MA was about 2.5 times more potent than PG in reversing MDR at equimolar concentrations. Increased accumulation of DOX in drugresistant cells that were treated simultaneously with MA was observed by flow cytometry. In vivo, using established human colon and breast carcinoma xenografts implanted s.c. in athymic mice, the combined therapy with MA and DOX resulted in enhanced antitumor activity relative to that of DOX alone in the MDR sublines. These results suggest that MA may be a promising clinical MDR-reversing agent.

UR - http://www.scopus.com/inward/record.url?scp=0028283470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028283470&partnerID=8YFLogxK

U2 - 10.1007/BF00685925

DO - 10.1007/BF00685925

M3 - Article

C2 - 8194172

AN - SCOPUS:0028283470

VL - 34

SP - 96

EP - 102

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -